ADJUVANT RIBOCICLIB PLUS NONSTEROIDAL AROMATASE INHIBITOR THERAPY IN PATIENTS WITH HR-POSITIVE/HER2-NEGATIVE EARLY BREAST CANCER: 5-YEAR FOLLOW-UP OF NATALEE EFFICACY OUTCOMES AND UPDATED OVERALL SURVIVAL.